> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Eton Pharmaceuticals NDA for Liquid Topiramate
- URL: https://www.fdaweb.com/eton-pharmaceuticals-nda-for-liquid-topiramate/
- Published: 2020-10-07T12:00:00.000Z
- Updated: 2026-09-14T16:31:38.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147827

Eton Pharmaceuticals has submitted an NDA for topiramate oral solution as a monotherapy for treating partial-onset or primary general tonic-clonic seizures in patients two years age and older; adjunctive therapy for treatment of partial-onset seizures, including seizures associated with Lennox-Gastaut syndrome in patients two years of age and older; and as preventative treatment of migraine in patients 12 years of age and older. “Topiramate is one of the most widely compounded oral liquids, and our product addresses the unmet need for pediatric-friendly formulations of the molecule,” the company says. Topiramate is currently FDA-approved only in tablet and capsule form, it says, adding that the market for oral topiramate is more than $800 million annually.